WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases.
The Wilms' tumor gene WT1 is overexpressed in various types of solid tumors, including lung and breast cancer and WT1 protein is a tumor antigen for these malignancies. In phase I clinical trials of WT1 peptide-based cancer immunotherapy, two patients with advanced lung cancer were intradermally injected with 0.3 mg of an HLA-A*2402-restricted, 9-mer WT1 peptide emulsified with Montanide ISA51 adjuvant. Consecutive WT1 vaccination at 2-week intervals resulted in a reduction in tumor markers such as chorio-embryonic antigen (CEA) and sialyl Lewis (x) (SLX) and by a transient decrease in tumor size. No adverse effects except for local erythema at the injection sites of WT1 vaccine were observed. These results provided us with the first clinical evidence demonstrating that WT1 peptide-based immunotherapy should be a promising treatment for patients with lung cancer.
Tsuboi
Akihiro
A
Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Japan.
Oka
Yoshihiro
Y
Osaki
Tadashi
T
Kumagai
Toru
T
Tachibana
Isao
I
Hayashi
Seiji
S
Murakami
Masaki
M
Nakajima
Hiroko
H
Elisseeva
Olga A
OA
Fei
Wu
W
Masuda
Tomoki
T
Yasukawa
Masaki
M
Oji
Yusuke
Y
Kawakami
Manabu
M
Hosen
Naoki
N
Ikegame
Kazuhiro
K
Yoshihara
Satoshi
S
Udaka
Keiko
K
Nakatsuka
Shin-Ichi
S
Aozasa
Katsuyuki
K
Kawase
Ichiro
I
Sugiyama
Haruo
H
D000368:Aged; D000951:Antigens, Neoplasm / Q000008:administration & dosage* / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000009:adverse effects / Q000235:genetics* / Q000276:immunology* / Q000627:therapeutic use; D016503:Drug Delivery Systems / Q000009:adverse effects / Q000379:methods; D005260:Female; D015234:HLA-A Antigens / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008175:Lung Neoplasms / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D016896:Treatment Outcome; D025721:WT1 Proteins / Q000008:administration & dosage* / Q000276:immunology / Q000627:therapeutic use
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D015234:HLA-A Antigens; D010446:Peptide Fragments; D025721:WT1 Proteins